Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$5.68-1.05%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PHAT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“We continue to grow VOQUEZNA prescribing depth among GI providers and have implemented several initiatives designed to make it easier for physicians to prescribe and patients to obtain our first-in-…
Stated in 3 of 3 supplied quarters. Management reported: “The increase was due to continued growth from execution of Phathom’s commercial strategy.” “After achieving the first million prescriptions just over two years into launch, Phathom reached its second million filled prescriptions less than a year later.” Revenue was $84.722 million in 2026-Q3.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““We continue to grow VOQUEZNA prescribing depth among GI providers and have implemented several initiatives designed to make it easier for physicians to prescribe and patients to obtain our first-in-…”
“We believe VOQUEZNA has the potential to reach $1 billion in annual revenue through our focus on gastroenterology providers, with an additional $1 billion annual opportunity through expanded engageme…”
““We believe there is a path to $1 billion annual revenue in gastroenterology prescriptions, and we are encouraged by the strength of our new-to-brand prescription momentum.”
“We have established a stronger financial foundation through continued revenue growth and disciplined expense management, while maintaining the flexibility to invest in our commercial and clinical de…
Stated in 3 of 3 supplied quarters. Management reported: “Non-GAAP operating expenses, excluding stock-based compensation, were $60.5 million, compared to $49.3 million for third quarter 2025.” ““Our third quarter results reflect Phathom’s significant financial transformation, with revenue growth of 71% year over year and positive cash flow from operations for the second consecutive quarter,” said Sanjeev Narula, Chief Financial and Business Officer of Phathom .”
““We have established a stronger financial foundation through continued revenue growth and disciplined expense management, while maintaining the flexibility to invest in our commercial and clinical de…”
“Our second quarter financial performance demonstrates the continued strengthening of our financial profile as we delivered record quarterly revenue and achieved operating profitability, excluding sto…”
““We maintained disciplined operations, reducing year-over-year cash operating expenses by more than 40%, while continuing to invest in our commercial organization and clinical pipeline.”
The first subject has been dosed, and sites are currently enrolling across the U.S. Topline results are expected in the first quarter 2028.
Stated in 3 of 3 supplied quarters. Management reported: “The first subject has been dosed, and sites are currently enrolling across the U.S. Topline results are expected in the first quarter 2028.” “The first subject has been dosed, and sites are currently enrolling across the U.S. Topline results are expected in the first quarter 2028.”
“The first subject has been dosed, and sites are currently enrolling across the U.S. Topline results are expected in the first quarter 2028.”
“First subject enrollment for the planned Phase 3 trial is expected during the fourth quarter of 2026.”
“EoE Clinical Trial Update: • The Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA in patients with eosinophilic esophagitis (EoE) is enrolling ahead of schedule with topline results now anticipated…”
[/TABLE] Third Quarter 2026 Financial Results: [TABLE] • | Revenue: Net revenues for the third quarter 2026 were $84.7 million, an increase of $35.2 million compared to $49.5 million for third quarte…
Stated in 1 of 3 supplied quarters. Management reported: “On October 23, 2026, FDA opened a public comment docket on issues raised in the litigation, with comments due November 23, 2026.” “Phathom intends to vigorously defend its statutory exclusivities.”
“[/TABLE] Third Quarter 2026 Financial Results: [TABLE] • | Revenue: Net revenues for the third quarter 2026 were $84.7 million, an increase of $35.2 million compared to $49.5 million for third quarte…”
Continue focus on achieving operating profitability excluding stock-based compensation starting in Q3 2026 and for full year 2026.
Over the trailing year it converted 2.49x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
12 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-04.